C620R mutation of the murine ret proto-oncogene: loss of function effect in homozygotes and possible gain of function effect in heterozygotes - PubMed (original) (raw)

. 2007 Jul 15;121(2):292-300.

doi: 10.1002/ijc.22378.

Aldamaria Puliti, Elena Bonora, Cecilia Evangelisti, Valerio Conti, Wei-Min Tong, Jean-Jacques Medard, Marie-France Lavoué, Nathalie Forey, Lily C Wang, Serge Manié, Gérard Morel, Mireille Raccurt, Zhao-Qi Wang, Giovanni Romeo

Affiliations

• PMID: 17372903
• DOI: 10.1002/ijc.22378

C620R mutation of the murine ret proto-oncogene: loss of function effect in homozygotes and possible gain of function effect in heterozygotes

Luo Yin et al. Int J Cancer. 2007.

Abstract

Germline RET mutations are responsible for different inherited disorders: Hirschsprung disease (congenital aganglionic megacolon), caused by loss of function mutations, familial medullary thyroid carcinoma and multiple endocrine neoplasia type 2, caused by gain of function mutations. Intriguingly, some RET mutations, including C620R, are associated with both types of diseases. To investigate the dual role of such RET mutations, a mouse model with a targeted mutation ret(C620R) was generated. ret(C620R/C620R) offspring die during the first postnatal day, and show kidney agenesis and intestinal aganglionosis. Decreased outgrowth of the Ret-positive cells was observed in ret(C620R/C620R) neuronal cell cultures, which is suggestive of an impaired migration, proliferation or survival of the Ret-expressing cells. Electronmicroscopy revealed the absence of membrane-bound Ret in ret(C620R/C620R) cells as compared to ret(+/+) and ret(+/C620R) cells. On the other hand, aged ret(+/C620R) mice develop precancerous lesions in the adrenal gland or in the thyroid. Our results suggest that the ret(C620R) mutation has a loss of function effect in homozygotes and exhibits a dominant gain of function effect with low penetrance causing hyperplasia in heterozygotes.

(c) 2007 Wiley-Liss, Inc.

PubMed Disclaimer

Similar articles

• The Ret(C620R) mutation affects renal and enteric development in a mouse model of Hirschsprung's disease.
  Carniti C, Belluco S, Riccardi E, Cranston AN, Mondellini P, Ponder BA, Scanziani E, Pierotti MA, Bongarzone I. Carniti C, et al. Am J Pathol. 2006 Apr;168(4):1262-75. doi: 10.2353/ajpath.2006.050607. Am J Pathol. 2006. PMID: 16565500 Free PMC article.
• RET proto-oncogene testing in infants presenting with Hirschsprung disease identifies 2 new multiple endocrine neoplasia 2A kindreds.
  Fialkowski EA, DeBenedetti MK, Moley JF, Bachrach B. Fialkowski EA, et al. J Pediatr Surg. 2008 Jan;43(1):188-90. doi: 10.1016/j.jpedsurg.2007.09.043. J Pediatr Surg. 2008. PMID: 18206480
• RET haplotype, not linked to the C620R activating mutation, associated with Hirschsprung disease in a novel MEN2 family.
  Quedas EP, Longuini VC, Sekiya T, Coutinho FL, Toledo SP, Tannuri U, Toledo RA. Quedas EP, et al. Clinics (Sao Paulo). 2012;67 Suppl 1(Suppl 1):57-61. doi: 10.6061/clinics/2012(sup01)11. Clinics (Sao Paulo). 2012. PMID: 22584707 Free PMC article. Review.
• The RET p.G533C mutation confers predisposition to multiple endocrine neoplasia type 2A in a Brazilian kindred and is able to induce a malignant phenotype in vitro and in vivo.
  Oliveira MN, Hemerly JP, Bastos AU, Tamanaha R, Latini FR, Camacho CP, Impellizzeri A, Maciel RM, Cerutti JM. Oliveira MN, et al. Thyroid. 2011 Sep;21(9):975-85. doi: 10.1089/thy.2010.0190. Epub 2011 Aug 11. Thyroid. 2011. PMID: 21834681
• RET receptor signaling: dysfunction in thyroid cancer and Hirschsprung's disease.
  Asai N, Jijiwa M, Enomoto A, Kawai K, Maeda K, Ichiahara M, Murakumo Y, Takahashi M. Asai N, et al. Pathol Int. 2006 Apr;56(4):164-72. doi: 10.1111/j.1440-1827.2006.01942.x. Pathol Int. 2006. PMID: 16634961 Review.

Cited by

• Renal aplasia in humans is associated with RET mutations.
  Skinner MA, Safford SD, Reeves JG, Jackson ME, Freemerman AJ. Skinner MA, et al. Am J Hum Genet. 2008 Feb;82(2):344-51. doi: 10.1016/j.ajhg.2007.10.008. Epub 2008 Jan 31. Am J Hum Genet. 2008. PMID: 18252215 Free PMC article.
• Increased RET Activity Coupled with a Reduction in the RET Gene Dosage Causes Intestinal Aganglionosis in Mice.
  Okamoto M, Uesaka T, Ito K, Enomoto H. Okamoto M, et al. eNeuro. 2021 Jun 3;8(3):ENEURO.0534-20.2021. doi: 10.1523/ENEURO.0534-20.2021. Print 2021 May-Jun. eNeuro. 2021. PMID: 33958373 Free PMC article.
• Sprouty1 is a candidate tumor-suppressor gene in medullary thyroid carcinoma.
  Macià A, Gallel P, Vaquero M, Gou-Fabregas M, Santacana M, Maliszewska A, Robledo M, Gardiner JR, Basson MA, Matias-Guiu X, Encinas M. Macià A, et al. Oncogene. 2012 Aug 30;31(35):3961-72. doi: 10.1038/onc.2011.556. Epub 2011 Dec 12. Oncogene. 2012. PMID: 22158037 Free PMC article.
• Overexpression of miR-218 inhibits hepatocellular carcinoma cell growth through RET.
  Sui C, Xu F, Shen W, Geng L, Xie F, Dai B, Lu J, Zhang M, Yang J. Sui C, et al. Tumour Biol. 2015 Mar;36(3):1511-8. doi: 10.1007/s13277-014-2679-1. Epub 2014 Nov 6. Tumour Biol. 2015. PMID: 25374061
• Mutations in RAD21 disrupt regulation of APOB in patients with chronic intestinal pseudo-obstruction.
  Bonora E, Bianco F, Cordeddu L, Bamshad M, Francescatto L, Dowless D, Stanghellini V, Cogliandro RF, Lindberg G, Mungan Z, Cefle K, Ozcelik T, Palanduz S, Ozturk S, Gedikbasi A, Gori A, Pippucci T, Graziano C, Volta U, Caio G, Barbara G, D'Amato M, Seri M, Katsanis N, Romeo G, De Giorgio R. Bonora E, et al. Gastroenterology. 2015 Apr;148(4):771-782.e11. doi: 10.1053/j.gastro.2014.12.034. Epub 2015 Jan 6. Gastroenterology. 2015. PMID: 25575569 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Wiley

• Molecular Biology Databases

  • Mouse Genome Informatics (MGI)